So much competition. This Pfizer deal is a massive threat to Immutep’s push into NSCLC. PD-L1/VEGF bispecifics are the hottest thing next to ADC’s in oncology. Immutep needs more combinations and indications yesterday. Development has been too slow.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
22.5¢ |
Change
-0.005(2.17%) |
Mkt cap ! $332.2M | |||
| Open | High | Low | Value | Volume |
| 23.0¢ | 23.5¢ | 22.5¢ | $586.9K | 2.578M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 28 | 308758 | 22.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.0¢ | 400337 | 33 |
View Market Depth
| Last trade - 12.28pm 25/06/2025 (20 minute delay) ? |
| IMM (ASX) Chart |